Uloric Lawsuit Investigation: Risk of Heart Attack, Stroke
Last Updated on November 21, 2019
Important Information
Attorneys working with ClassAction.org are no longer investigating this matter. The information here is for reference only. A list of open investigations and lawsuits can be viewed here.
Case Update
- November 21, 2019
- Attorneys working with ClassAction.org have decided to close their investigation into this matter. The information below is therefore for reference only. If you have questions regarding your rights in regard to Uloric, contact an attorney in your area. To see a current list of investigations, please visit this page.
At A Glance
- This Alert Affects:
- Patients and loved ones of patients who took Uloric (febuxostat) and suffered a heart attack, stroke, heart-related death, or another critical cardiovascular event.
- What Is Uloric?
- Uloric (febuxostat) is a medication that was approved by the FDA in 2009 to treat gout by lowering uric acid levels in the blood.
- What’s Going On?
- Attorneys believe the maker of Uloric may have failed to warn patients of severe heart-related risks associated with using the drug. They are investigating whether lawsuits can be filed.
- How Could a Lawsuit Help?
- A lawsuit could help repay medical bills or other damages for people who experienced heart complications or stroke after taking Uloric.
Attorneys are investigating whether lawsuits can be filed on behalf of patients who took Uloric and suffered a heart attack, stroke, heart disease, cardiac-related death, or other heart-related complication.
It’s believed that Takeda Pharmaceuticals, the maker of Uloric, failed to warn patients about the severe heart-related risks of using the drug.
What’s Behind the Investigation?
It is believed that Takeda Pharmaceuticals has been selling Uloric (which contains the active ingredient febuxostat) for the past 10 years without properly warning patients about the cardiovascular risks associated with taking the drug.
When Uloric was first approved in 2009, the FDA directed Takeda to conduct post-market safety tests due to concerns that the drug may present a higher risk for heart problems than allopurinol, one of the only gout treatments on the market at the time.
The result of the tests, published in the New England Journal of Medicine, confirmed that there was an increased risk of cardiovascular death for people taking Uloric as compared to allopurinol.
Yet it wasn’t until late February 2019 that Takeda updated Uloric’s labeling – and only after the FDA required the company to include a black box warning, the agency’s strongest warning, about the drug’s increased risk of death.
The FDA has recently advised doctors to only prescribe Uloric for patients who can’t be treated effectively or experience severe side effects with allopurinol.
What Health Risks Are Associated with Taking Uloric?
It’s believed that Uloric can cause heart problems, heart disease, heart palpitations, heart attack, stroke, and other critical cardiovascular events.
How Can a Lawsuit Help?
A lawsuit could provide compensation for:
- Medical bills
- Funeral expenses
- Pain and suffering
- Lost wages
- Loss of enjoyment of life
Before commenting, please review our comment policy.